An association between non-opioid analgesic agents and chronic kidney disease has long been suspected. The presumed development of chronic renal impairment following protracted excessive use of non-opioid analgesia is known as analgesic nephropathy. Many accept analgesic nephropathy as a real entity despite a paucity of robust scientific evidence. The weight of available observational literature suggests that long-term ingestion of paracetamol and combination mixtures of aspirin and paracetamol probably contribute to chronic renal impairment, however there is no convincing data to implicate non-steroidal anti-inflammatory drugs or aspirin monotherapy. While controversy persists most physicians consider all non-narcotic analgesics nephrotoxic and discourage heavy use where possible.
De BroeMElseviersM. Analgesic nephropathy. N Engl J Med. 1998;338(7):446–52.
2.
ChangSMathewTMcDonaldS. Analgesic nephropathy and renal replacement therapy in Australia: Trends, comorbidities and outcomes. Clin J Am Soc Nephrol. 2008;3(3):768–76.
3.
BuckalewVScheyM. Renal disease from habitual antipyretic analgesic consumption: An assessment of the epidemiologic evidence. Medicine. 1986;11(1):291–303.
4.
De BroeMElseviersM. Over the counter analgesic use. J Am Soc Nephrol. 2009;20:2098–2103.
5.
PinterIMatyusJCzeganyZHarsanyiJHomokiMKassaiM, et al. Analgesic nephropathy in Hungary: The HANS study. Nephrol Dial Transplant. 2004;19(4):840–43.
6.
BennettWDe BroeM. Analgesic nephropathy: A preventable renal disease. N Engl J Med. 1989;320(19):1269–71.
7.
DelzellEShapiroS. A review of epidemiologic studies of non-narcotic analgesics and chronic renal disease. Medicine. 1998;77(2):102–21.
8.
DubachURosnerBStuemerT. An epidemiologic study of abuse of analgesic drugs: Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med. 1991;324(3):155–60.
9.
MihatschMKhanlariBBrunnerF. Obituary to analgesic nephropathy: An autopsy study. Nephrol Dial Transplant. 2006;21:3139–45.
10.
NoelsLElseviersMDe BroeM. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: A comparative study in France, Sweden and Belgium. Nephrol Dial Transplant. 1995;10:167–74.
11.
BrunnerFSelwoodN. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol Dial Transplant. 1994;9:1371–76.
12.
GaultMWilsonD. Analgesic nephropathy in Canada: Clinical syndrome, management and outcome. Kidney Int. 1978;13:58–63.
13.
MabeckCWichmannB. Mortality from chronic interstitial nephritis and phenacetin consumption in Denmark. Acta Med Scand. 1979;205(7):599–601.
14.
NanraR. Analgesic nephropathy in the 1990s: An Australian perspective. Kidney Int. 1993;44(Suppl 42):86–92.
15.
WilsonDGaultH. Declining incidence of analgesic nephropathy in Canada. Can Med Ass J. 1982;127:500–02.
16.
MichielsenPDe SchepperP. Trends of analgesic nephropathy in two high-endemic regions with different legislation. J Am Soc Nephrol. 2001;12:550–56.
DubachURosnerBPfisterE. Epidemiologic study of abuse of analgesics containing phenacetin: Renal morbidity and mortality (1968-1979). N Engl J Med. 1983;308(7):357–62.
19.
McCredieMStewardJMathewTDisneyAFordJ. The effect of withdrawal of phenacetin-containing analgesics on the incidence of kidney and urothelial cancer and renal failure. Clin Nephrol. 1989;31:35–39.
20.
PrescottL. Analgesic nephropathy: A reassessment of the role of phenacetin and other analgesics. Drugs. 1982;23(1):75–149.
21.
StewartJGalleryE. Analgesic abuse and kidney disease. Aust NZ J Med. 1976;6:498–508.
22.
HenrichW. Southwestern internal medicine conference: Analgesic nephropathy. Am J Med Sci. 1988;295(6):561–68.
23.
CurhanGKnightERosnerBHankinsonSStampferM. Lifetime non-narcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519–24.
24.
SandlerDSmithJWeinbergCBuckalewVDennisVBlytheW, et al. Analgesic use and chronic renal disease. N Engl J Med. 1989;320(19):1238–43.
25.
PernegerTWheltonPKlagM. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal anti-inflammatory drugs. N Engl J Med. 1994;331(25):1675–79.
26.
SteenlandKThunMFergusonWPortF. Occupational and other exposures associated with male end-stage renal disease: A case control study. Am J Public Health. 1990;80(2):153–59.
27.
KelkarMClevesMFosterHHoganWJamesLMartinB. Acute and chronic acetaminophen use and renal disease: A case control study using pharmacy and medical claims. J Manag Care Pharm. 2012;18(3):234–46.
28.
AgodoaLFrancisMEggersP. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis. 2008;51(4):573–83.
29.
FergusonIJohnsonFReayBWigleyR. Aspirin, phenacetin, and the kidney: A rheumatism clinic study. Med J Aust. 1977;1(26):950–54.
30.
CaugheyDIsdaleITweedJTreadwellBLaingJKirkJ, et al. Aspirin and the kidney: New Zealand Rheumatism Association Study. BMJ. 1974;1:593–96.
31.
RexrodeKBuringJGlynnRStampferMYoungmanLGazianoM. Analgesic use and renal function in men. JAMA. 2001;286:315–21.
32.
IbanezLMorlansMVidalXMartinezMLaporteJR. Case control study of regular analgesic and non-steroidal anti-inflammatory use and end-stage renal disease. Kidney Int. 2005;67:2393–98.
33.
MacklonACraftAThompsonMKerrD. Aspirin and analgesic nephropathy. BMJ. 1974;1:597–600.
34.
EmkeyRMillsJ. Aspirin and analgesic nephropathy. JAMA. 1982;247(1):55–57.
35.
ElseviersMDe BroeM. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int. 1995;48:1912–19.
36.
ForedMEjerbladELinbladPFryzekJDickmanPSignorelloL, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345(25):1801–08.
37.
IngrasciottaYSultanaJGiorgianniFFontanaASantangeloATariD, et al. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study. PLoS One. 2015;10(4):E0122899.
38.
Van Der WoudeFHeinemannLGrafHLewisMMoehnerSAssmannA, et al. Analgesic use and ESRD in younger age: A case controls study. BMC Nephrology. 2007;8(15):1–12.
39.
MichielsenPHeinemannLMihatschMSchnuellePGrafHKochKM. Non-phenacetin analgesics and analgesic nephropathy: Clinical assessment of high users from a case control study. Nephrol Dial Transplant. 2009;24:1253–59.
40.
SandlerDBurrRWeinbergC. Non-steroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Int Med. 1991;115(3):165–72.
41.
GoochKCulletonBMannsBZhangJAlfonsoHTonelliM, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):281–87.
42.
NderituPDoosLJonesPDaviesSKadamU. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: A systematic review. Family Practice. 2013;30:247–55.
43.
JosephyDMannervikBMolecular Toxicology. 2nd ed. Oxford: Oxford University Press; 2006. p. 514.
44.
LanesSDelzellEDreyerNRothmanK. Analgesics and kidney disease. Int J Epidemiol. 1986;15(4):454–55.
45.
HenrichWAgodaLBarrettBBennettWBlantzRBuckalewV, et al. Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kid Dis. 1996;27(1):162–65.
46.
FeinsteinAHeinemannLCurhanGDelzellEDeSchepperPFoxJ, et al. Relationship between nonphenacetin combined analgesics and nephropathy: A review. Kidney Int. 2000;58:2259–64.
